Health · 4 June 2026

New ovarian cancer drug approved for 400 women

Hundreds of women in England with advanced ovarian cancer can now get a new life-extending drug, the first in over 20 years. NHS England approved mirvetuximab soravtansine, a targeted therapy, after NICE recommended it for patients whose cancer resists chemotherapy. This new treatment helped patients live 16.5 months on average, compared to 12.8 months with standard chemotherapy.

By BriefTea Editorial · 4 June 2026 at 11:34

Reported by Guardian · How we write briefs

Get the app

More briefs

HealthCorrecting hearing loss can cut dementia risk by almost half HealthMan changes life after doctor warns liver disease could kill him HealthSweetener used in chewing gum and jam linked to strokes and heart attacks HealthMouth cancer rates up a third in UK, often with no obvious cause HealthBox breathing helps calm stress and reduce anxiety, say experts HealthNHS managers warn spiralling costs could disrupt ADHD and autism care More health stories → Browse all stories →